Comparing MiMedx Group (MDXG) & The Competition

MiMedx Group (NASDAQ: MDXG) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its peers? We will compare MiMedx Group to similar companies based on the strength of its analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Profitability

This table compares MiMedx Group and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MiMedx Group 7.48% 15.95% 11.13%
MiMedx Group Competitors -127.18% -36.38% -10.25%

Valuation & Earnings

This table compares MiMedx Group and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
MiMedx Group $283.32 million $32.97 million 72.74
MiMedx Group Competitors $827.23 million $159.49 million 36.27

MiMedx Group’s peers have higher revenue and earnings than MiMedx Group. MiMedx Group is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

MiMedx Group has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, MiMedx Group’s peers have a beta of 1.06, suggesting that their average share price is 6% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for MiMedx Group and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiMedx Group 1 0 3 1 2.80
MiMedx Group Competitors 174 1131 2471 89 2.64

MiMedx Group currently has a consensus price target of $16.00, indicating a potential upside of 15.77%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 10.22%. Given MiMedx Group’s stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than its peers.

Insider & Institutional Ownership

60.4% of MiMedx Group shares are held by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 12.4% of MiMedx Group shares are held by insiders. Comparatively, 11.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

MiMedx Group beats its peers on 8 of the 13 factors compared.

MiMedx Group Company Profile

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Receive News & Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1


Leave a Reply

 
© 2006-2017 BBNS.